Genmab announced termination of clinical development for acasunlimab, a bispecific antibody that previously had been co‑developed with BioNTech before that partner exited the asset. The company confirmed it will stop further work on the bispecific after internal review of the program and available clinical data. Acasunlimab targeted dual immune checkpoints via a bispecific design; BioNTech’s earlier withdrawal and Genmab’s decision to end development highlight the commercial and translational risks in complex multispecific immunotherapies. Investors and collaborators will monitor how Genmab reallocates resources and whether any data or assets are outlicensed. The move reduces near‑term pipeline breadth for Genmab but may sharpen focus on other oncology and antibody programs in its portfolio.